News

In a study performed at MD Anderson Cancer Center, there was no significant overall survival impact in patients with anaplastic thyroid cancer who had prior differentiated thyroid cancer, concomitant differentiated thyroid cancer, and prior non thyroid cancers.

Rebecca Silbermann, MD, MMS, discusses the relevance of patient-reported outcomes from the phase 2 GRIFFIN study and the importance of individualizing treatment for patients with multiple myeloma.

TP-1287, an investigational oral phosphate prodrug of the CDK9 inhibitor alvocidib, has been granted an orphan drug designation by the FDA for patients with Ewing sarcoma.

CB-011 has received a fast track designation from the FDA for the treatment of relapsed/refractory multiple myeloma and is being investigated in the ongoing CaMMouflage study.

The phase 3 Karmma-3 trial of ide-cel in patients with triple-class-exposed relapsed/refractory multiple myeloma generated significantly improved progression-free survival and overall response rates vs standard regimens.

A new apalutamide tablet has become available for oncologists in the United States who treat non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.

Gayathri Ravi, MD, discusses the role minimal residual disease plays in decision making and treating patients with hematologic malignancies.

Mixed study results for ibrutinib have led the developer to voluntarily withdraw the agent from the United States market for the treatment of mantle cell and marginal zone lymphoma subgroups.

During a live webinar, Hussein Tawbi, MD, PhD, discussed first-line therapy for patients with stage IV melanoma, particularly the impact of targeting both PD-1 and LAG3 in these patients by using nivolumab and relatlimab.

During a Targeted Oncology™ Case-Based Roundtable™ event, Hetty E. Carraway, MD, MBA, discussed with participants diagnosing and treating patients with BPDCN, as well as the remaining challenges in this space.

The addition of dostarlimab to standard combination chemotherapy in the phase 3 RUBY study showed a significant survival improvement in patients with primary advanced or recurrent endometrial cancer.

A first-in-human study is assessing the safety, efficacy, and pharmacokinetics of DK210 as a monotherapy and in combination with immunotherapy, radiotherapy, or chemotherapy for patients with EGFR-expressing solid tumors.

In the KEYNOTE-045 and KEYNOTE-052 trials, pembrolizumab continued to led to durable responses with no new safety signals after 5 years.

With 1.5 years of follow-up, the confirmed objective response rate was 92.5% among patients who were ROS1 tyrosine kinase inhibitor-naïve and 52.6% in crizotinib-pretreated patients in the phase 2 TRUST-I trial.

A Tennessee Oncology location in Nashville was the first to dose the novel c-MET antibody-drug conjugate, MYTX-011, as part of the phase 1 KisMET-01 clinical trial.

Neither the LEAP-003 nor LEAP-017 studies study showed survival benefit with pembrolizumab plus lenvatinib for patients with melanoma or colorectal cancer.

During a Targeted Oncology™ Case-Based Roundtable™, Robert W. Holloway, MD, discussed with participants later-line systemic therapy options for patients with recurrent/metastatic endometrial cancer.

In an interview with Targeted Oncology, Bridget Koontz, MD, discussed burnout and its importance in experts treating patients with cancer.

In an interview with Targeted Oncology™, Yousef Zakharia, MD discussed evidence supporting both doublet and triplet therapy for the treatment of previously untreated, advanced/metastatic renal cell carcinoma.

The investigational new drug, SynKIR-110, has received a fast track designation from the FDA for patients with mesothelioma and is continuing to be evaluated in a phase 1 trial.

During a Targeted Oncology™ Case-Based Roundtable™, Edward S. Kim, MD, MBA, discussed with participants utilizing chemoradiation and immunotherapy for patients with non–small cell lung cancer.

According to follow-up data from EMPOWER-Lung 3, cemiplimab plus platinum-doublet chemotherapy maintained clinically improvements in advanced non–small cell lung cancer.

Carolyn Owen, MD, discusses minimal residual disease as an area of research in the chronic lymphocytic leukemia space.

In the phase 3 DUO-O study, combing 5 targeted and chemotherapy agents for the treatment of newly diagnosed, advanced, high-grade epithelial ovarian cancer with or without BRCA mutations has shown to extend progression-free survival.

Multiple trials and techniques have evaluated treatment with HLX02 compared with trastuzumab. Now, the FDA has accepted the biologics license application HLX02 for patients with HER2-overexpressing metastatic breast cancer, breast cancer, gastric cancer, and gastroesophageal junction adenocarcinoma.

The largest registrational study of immune checkpoint inhibitor therapy in relapsed/refractory extranodal natural killer/T-cell lymphoma showed potent and durable antitumor activity with sugemalimab.

Ariel Perez, MD, discusses polatuzumab vedotin in combination with bendamustine and rituximab since garnering approval from the FDA and studies that evaluated the combination.

Data from a phase 1/2 study of BDC-1001 alone or with nivolumab supports selection of a recommended phase 2 dose, advancement of further phase 2 studies, and assessment of the agent in combination with pertuzumab.

Results from the phase 2 PHAROS trial of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic non–small cell lung cancer has led the FDA to accept supplemental new drug applications for the agents. Further data will be presented at an upcoming medical meeting.